Bio-evaluation of doxorubicin (DOX)-incorporated hydroxyapatite (HAp)-chitosan (CS) nanocomposite triggered on osteosarc
- PDF / 2,157,047 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 82 Downloads / 175 Views
ORIGINAL RESEARCH
Bio-evaluation of doxorubicin (DOX)-incorporated hydroxyapatite (HAp)-chitosan (CS) nanocomposite triggered on osteosarcoma cells Saikat Ghosh 1 & Sampad Ghosh 2 & Nabakumar Pramanik 1 Received: 11 February 2020 / Revised: 16 April 2020 / Accepted: 4 May 2020 # Springer Nature Switzerland AG 2020
Abstract A new strategic nanostructure consisting inorganic–organic combination for cancer dominancy has been successfully developed using doxorubicin (DOX)-assimilated hydroxyapatite (HAp) as filler and chitosan (CS) as matrix by a solution-based chemical method to access a new window in the field of drug delivery systems (DDS). In this research attempt, we have focussed to fetch an anticancer efficacy from a nanoassembly consisting of DOX-coated nanosized HAp and CS. Basically, HAp is a progressive ceramic biomaterial and has been synthesized by a simple in situ precipitation method, in which the reputed anticancer drug DOX was incorporated and the system was further modified by an extensively used polymer CS. CS is an organic polymer that can be obtained from different organic sources, which may provide mechanical strength to the nanocomposite by making interfacial bonding between them. Such a novel nanocomposite has been physicochemically characterized using Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), transmission electron microscopy (TEM) and particle size distribution (PSD). Also, the in vitro biocompatible assistance of the synthesized HAp and the anticancer activity of the newly derived nanocomposite were evaluated through a colorimetric assay (MTT assay). HAp remains biocompatible to osteosarcoma cells, whereas the DOX-HAp-CS nanocomposite produces a remarkable cytotoxicity towards cultured osteosarcoma cells. The prepared DOXHAp-CS nanocomposite may be potentially used as an anticancer agent for osteosarcoma inhibition. Keywords Nanocomposite . Chitosan . Osteosarcoma . Doxorubicin . Cytotoxicity . Hydroxyapatite
1 Introduction Development of new potential nanodevices has gained a remarkable impact in the field of biomedical research and also confirms the nanotechnological acquisitions in this particular field of research. Management of osteosarcoma is one of the major challenging tasks in biomedical research areas. Osteosarcoma and osteogenic sarcoma are the most frequent malignant bone tumours in childhood and adolescence, but osteosarcoma can be developed at any age. Nanotherapeutical approaches are the extensively used traditions in cancer therapy from the very beginning to accomplish remarkable therapeutic effects against the cancer cells without affecting the normal * Nabakumar Pramanik [email protected] 1
Department of Chemistry, National Institute of Technology, Arunachal Pradesh, Yupia 791112, India
2
Department of Chemistry, Nalanda College of Engineering, Nalanda, Bihar 803108, India
cells. The hybrid nanostructural materials are significant for various cancerous applications such as prognosis, diagnosis and prophylaxis. Those materials are wel
Data Loading...
